{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:14:37Z","timestamp":1757780077431,"version":"3.41.2"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Muscle\u2010invasive urothelial carcinoma (MIUC) is a highly aggressive cancer associated with poor prognosis. Despite advancements in treatment, the optimal therapeutic approach remains unclear. Immune checkpoint inhibitors, when added to chemotherapy, have shown promise in improving patient outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>This study aimed to evaluate the efficacy and safety of adjuvant tislelizumab combined with gemcitabine\/cisplatin (Tisle+GC) compared to GC alone in patients with high\u2010risk MIUC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials &amp; Methods<\/jats:title><jats:p>We conducted a retrospective analysis of 117 patients with histologically confirmed pT3\/4 and pN+ MIUC treated at our center between October 2016 and March 2023. Eligible patients received either Tisle+GC or GC alone, excluding those with prior neoadjuvant therapy. We compared disease\u2010free survival (DFS), overall survival (OS), and treatment\u2010related adverse events (AEs) between the two groups using Cox proportional hazards models and Kaplan\u2013Meier estimates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The Tisle+GC group showed significantly longer median DFS (19.08 vs. 9.06 months, HR\u2009=\u20090.114, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and OS (20.07 vs. 10.63\u2009months, HR\u2009=\u20090.083, <jats:italic>p<\/jats:italic>\u2009=\u20090.026) compared to the GC group. Nerve tract invasion was identified as a significant predictor of poor outcomes (HR\u2009=\u200922.1, <jats:italic>p<\/jats:italic>\u2009=\u20090.003). Both groups experienced manageable grade 1\u20132 immune\u2010related AEs, with pruritus being the most common, followed by liver function abnormalities and thyroid disturbances. Nonhematologic toxicities in the Tisle+GC group included elevated aspartate aminotransferase and hyponatremia, while the GC group mainly reported vomiting. No treatment\u2010related fatalities occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The addition of tislelizumab to GC chemotherapy significantly improved both DFS and OS in high\u2010risk MIUC patients. The safety profile was manageable, with immune\u2010related AEs being predictable and not life\u2010threatening. The findings support the potential of Tisle+GC as an effective adjuvant therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Tisle+GC is a promising adjuvant treatment for high\u2010risk MIUC, offering improved survival outcomes with a manageable safety profile. Further prospective studies are needed to confirm these results and establish the long\u2010term benefits of this combination therapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70661","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T10:57:26Z","timestamp":1740049046000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Effectiveness of Tislelizumab With Gemcitabine\/Cisplatin Versus Gemcitabine\/Cisplatin Alone as Adjuvant Therapy for High\u2010Risk Muscle\u2010Invasive Urothelial Carcinoma: A Real\u2010World Study"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6121-8706","authenticated-orcid":false,"given":"Yanjun","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaihua","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Urology Meizhou People's Hospital  Meizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingliang","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Urology Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianghua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Urology Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Urology Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9526-3388","authenticated-orcid":false,"given":"Zhiming","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00004-8"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00363"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.011"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.08.016"},{"issue":"117","key":"e_1_2_11_6_1","first-page":"e117","article-title":"The Role of Neoadjuvant Chemotherapy for Patients With Variant Histology Muscle Invasive Bladder Cancer Undergoing Robotic Cystectomy: Data From the International Robotic Cystectomy Consortium","volume":"42","author":"Cooke I.","year":"2024","journal-title":"Urologic Oncology"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02543-0"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2158"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1265"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2265570"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1162580"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02568-1"},{"key":"e_1_2_11_14_1","first-page":"462","article-title":"Rationale and Design of a Prospective, Multicenter, Phase II Clinical Trial of Safety and Efficacy Evaluation of Long Course Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Total Mesorectal Excision for Locally Advanced Rectal Cancer (NCRT\u2010PD1\u2010LARC Trial)","volume":"22","author":"Yang Z.","year":"2022","journal-title":"BioMed Central"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/10732748231173475"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.01.016"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.12.001"},{"key":"e_1_2_11_19_1","first-page":"109","article-title":"Gemcitabine With Cisplatin and Nivolumab: Redefining Standard of Care for First\u2010Line Metastatic Urothelial Carcinoma?","volume":"5","author":"Mathew Thomas V.","year":"2024","journal-title":"Medicamundi"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1289\/EHP9895"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03400-z"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194813"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106680"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102023\u2010006887"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1226993"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007353"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.802467"},{"key":"e_1_2_11_28_1","first-page":"10472","article-title":"Clinical Efficacy and Safety of Adjuvant Immunotherapy (Tislelizumab) Plus Chemotherapy vs. Adjuvant Chemotherapy Alone in Lymph Node\u2010Positive Patients With Gastric Cancer After D2 Radical Resection: A Prospective, 2\u2010Arm, Phase II Study","volume":"27","author":"Shi J. W.","year":"2023","journal-title":"European Review for Medical and Pharmaceutical Sciences"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0545-2"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102315"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T22:44:35Z","timestamp":1744929875000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/cam4.70661"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70661","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"2024-10-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70661"}}